A universal infant rotavirus vaccine program in two delivery models: Effectiveness and adverse events following immunization

Carolyn Sanford, Joanne M Langley, Scott A Halperin, Mitchell Zelman, Mvrvp, Carolyn Sanford, Joanne M Langley, Scott A Halperin, Mitchell Zelman, Mvrvp

Abstract

Rotavirus is the most common cause of diarrhea leading to hospitalization in young children. Rotavirus vaccines are available in Canada but have not been introduced in all provinces. In a controlled trial, 2 study sites (Prince Edward Island and the Capital District Health Authority (District 9, Nova Scotia) introduced universal rotavirus vaccine programs for infants at 2 and 4 months of age beginning 1 December 2010, using public health nurse or general practitioner-delivery models, respectively. A third site (Saint John, NB) served as the non-intervention control setting. Vaccine coverage, rotavirus hospitalizations, intussusception and all-cause diarrhea were monitored. A universal rotavirus vaccine program with >90% coverage was associated with reductions in rotavirus-associated hospitalizations (from a peak of 52.8 hospitalizations/100,000 population to 0 hospitalizations) in infants < 12 months and 1 to < 2 y of age 12 months after program implementation. No apparent reduction occurred in the site with vaccine coverage of < 40%, or in the non-intervention control site. No cases of intussusception were associated with vaccine receipt, and no increase in all-cause diarrhea was observed. A universal infant rotavirus vaccine program with high coverage was associated with reductions in rotavirus and no safety signals; no reduction was observed in settings with low vaccine coverage.

Keywords: Clinical Trials registration; NCT01273077; Rotavirus vaccines; immunization programs; public health practice.

Figures

Figure 1.
Figure 1.
Rotavirus admissions in children

References

    1. Tate JE, Patel MM, Steele AD, Gentsch JR, Payne DC, Cortese MM, Nakagomi O, Cunliffe NA, Jiang B, Neuzil KM, et al. . Global impact of rotavirus vaccines. Expert Rev Vaccines 2010; 9(4):395-407; PMID:20370550;
    1. Strategic Advisory Group of Vaccine Experts World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 – conclusions and recommendations. Wkly Epidemiol Rec. 2009;84(23):220-36.
    1. National Advisory Committee on Immunization. Updated statement of the use of rotavirus vaccines. Can Commun Dis Rep. 2010;36(ACS-4):1-36.
    1. Buigues RP, Duval B, Rochette L, Boulianne N, Douville-Fradet M, Dery P, De Serres G. Hospitalizations for diarrhea in Quebec children from 1985 to 1998: Estimates of rotavirus-associated diarrhea. Can J Infect Dis 2002; 13(4):239-44; PMID:18159396
    1. National Advisory Committee on Immunization. Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine. Can Commun Dis Rep. 2008;34(ACS-1):33.
    1. Canadian Immunization Committee. Recommendations for Rotavirus Immunization Programs Ottawa, ON: Public Health Agency of Canada; 2014 [cited 2014 01 March]. 24 January 2014: Available from: .
    1. Zelman M, Sanford C, Neatby A, Halperin BA, MacDougall D, Rowswell C, Langley JM, Halperin SA; Maritime Universal Rotavirus Vaccination Program (MURVP) . Implementation of a universal rotavirus vaccination program: Comparison of two delivery systems. BMC Public Health 2014; 14(1):908; PMID:25182067;
    1. Department of Health and Wellness. Prince Edward Island Reproductive Care Program Perinatal Database Report 2011 Charlottetown, PEI: Government of Prince Edward Island; 2013 [28 April 2014]. Available from: .
    1. Patel MM, Parashar UD, Santosham M, Richardson V. The rotavirus experience in Mexico: Discovery to control. Clini Infect Dis 2013; 56(4):548-51; PMID:23271788;
    1. McDermid A, Le Saux N, Grudeski E, Bettinger JA, Manguiat K, Halperin SA, Macdonald L, Déry P, Embree J, Vaudry W, et al. . Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals. BMC infectious diseases 2012; 12:306; PMID:23153184;
    1. Dummer TJ, Cui Y, Strang R, Parker L. Immunization completeness of children under two years of age in Nova Scotia, Canada. Can J Public Health 2012; 103(5):e363-7; PMID:23617989
    1. Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M. Canada's National Advisory Committee on Immunization (NACI): Evidence-based decision-making on vaccines and immunization. Vaccine 2010; 28 Suppl 1:A58-63; PMID:20412999;
    1. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010; 29(6):489-94; PMID:20354464
    1. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007–May 2008. MMWR Morbidity and mortality weekly report. 2008;57(25):697-700.
    1. Rha B, Tate JE, Payne DC, Cortese MM, Lopman BA, Curns AT, Parashar UD. Effectiveness and impact of rotavirus vaccines in the United States—2006–2012. Expert Rev Vaccines 2014; 13(3):365-76; PMID:24392657;
    1. Pitzer V, Viboud C, Lopman BA, Patel MM, Parashar UD, Grenfell B. Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. J R Soc Interface 2011; 8:1584-93; PMID:21508015;
    1. World Health Organization Global Advisory Committee on Vaccine Safety. J. Wkly Epidemiol Rec 2007; 82:252-9; PMID:17642098
    1. Bines J, Bentsi-Enchill A, Steele D. Post-marketing surveillance if rotavirus vaccine safety. In: Biologicals Va, editor. Geneva: World Health Organization; 2008.
    1. U.S. Food and Drug Administration. Update: Information on Rotarix - Labeling Revision Pertaining to Intussusception. In: Biologics VBa, editor. Washington, D.C.: U.S. Department of Health and Human Services; 201
    1. Brandt CD, Kim HW, Rodriguez WJ, Arrobio JO, Jeffries BC, Stallings EP, Lewis C, Miles AJ, Chanock RM, Kapikian AZ, et al. . Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol 1983; 18(1):71-8; PMID:6309901
    1. Zelman M, Sanford C, Neatby A, Halperin B, MacDougall D, Rowswell C, et al. . Implementation of a universal rotavirus vaccination program: comparison of two delivery systems. TBD. TBD.
    1. Statistics Canada. Census Profile 2011. Ottawa, ON: Government of Canada; 2014 [updated 20111 January 2014]. Available from: .
    1. GlaxoSmithKline Inc. Product Monograph Rotarix Mississauga, ON: GlaxoSmithKline Inc; 2014 [cited 2014 1 January]. Available from: .
    1. Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, Canadian Immunization Monitoring Program A . Substantial morbidity for hospitalized children with community-acquired rotavirus infections: 2005-2007 IMPACT surveillance in Canadian hospitals. Pediatr Infect Dis J 2010; 29(9):879-82; PMID:20467353;
    1. Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J, Murphy TM, Music S, Niu M, Varricchio F, et al. . Acute intussusception in infants and children as an adverse event following immunization: Case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22(5-6):569-74; PMID:14741146;

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner